Drs. Ross Camidge and Corey Langer give their views on more widespread availability of new mutation tests.

Dr. Sumanta (Monty) Pal reviews the current role of chemotherapy in the treatment of kidney cancer.

Dr. Phil Bonomi, from Rush University, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.

Dr. Karen Kelly of the University of California, Davis, provides her view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, TN expresses his practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

Dr. Sarah Goldberg from Yale Cancer Center describes the methods she uses to obtain tissue samples for molecular testing.

Dr. Lecia Sequist of Massachusetts General Hospital offers her insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent for lung cancer.

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, covers what surgery for pancreatic cancer entails, what the recovery process is like, and the importance of surgeon experience in outcomes.

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, covers what surgery for pancreatic cancer entails, what the recovery process is like, and the importance of surgeon experience in outcomes.

Dr. Rosalyn Juergens, McMaster University, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?